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Biological psychiatry has a long history of using somatic
therapies to treat neuropsychiatric illnesses and to under-
stand brain function. These methods have included neu-
rosurgery, electroconvulsive therapy, and, most recently,
transcranial magnetic stimulation. Fourteen years ago
researchers discovered that intermittent electrical stimu-
lation of the vagus nerve produces inhibition of neural
processes, which can alter brain electrical activity and
terminate seizures in dogs. Since then, approximately
6000 people worldwide have received vagus nerve stimu-
lation for treatment-resistant epilepsy. We review the
neurobiology and anatomy of the vagus nerve and provide
an overview of the vagus nerve stimulation technique. We
also describe the safety and potential utility of vagus nerve
stimulation as a neuroscience research tool and as a
putative treatment for psychiatric conditions. Vagus nerve
stimulation appears to be a promising new somatic inter-
vention that may improve our understanding of brain
function and has promise in the treatment of neuropsychi-
atric disorders. Biol Psychiatry 2000;47:287–295
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Historical Introduction
An Overview of Somatic Interventions (Table 1)
S
ince its inception, biological psychiatry has embraced
the use of somatic interventions for brain research and
clinical treatment. Indeed, many of the founders of the
55-year-old Society of Biological Psychiatry were re-
searchers who were interested in understanding the mech-
anisms of action of electroconvulsive therapy (ECT).
Although the revolution in neuropsychopharmacology
over the last 40 years has captured much interest, recent
advances in somatic interventions (e.g., physical, nonphar-
macological) are causing a resurgence of interest in other
methods that directly and, in some cases (transcranial
magnetic stimulation [TMS]), noninvasively affect brain
function. The field of ECT continues to advance, with
recent demonstrations of the need for dosage titration
(Sackeim et al 1987b) and regional specificity of ECT
effects (Sackeim et al 1987a, 1993) and even the recent
production of ECT-like seizures using magnetic instead of
electrical currents (Lisanby et al 1999). There has also
been considerable interest in TMS (without seizure pro-
duction), which holds promise as a research tool with
potential clinical applications (George and Belmaker
1999; George et al 1999).
The most anatomically discrete and most invasive
currently employed method of stimulating deep brain
structures is deep brain stimulation (DBS), in which a thin
electrode is inserted directly into the brain and different
currents are applied at varying depths until the desired
effects are found. Recently, high-frequency (.80 Hz)
electrical stimulation of the middle thalamus or subtha-
lamic nucleus has been found to be effective in Parkin-
son’s disease (Damier 1998; Limousin et al 1998).
Whereas DBS has the advantage over brain surgery
(pallidotomy) of being reversible, it has significant mor-
bidity and mortality associated with the implant procedure.
Although this technique has not been used to treat major
depression, mood effects of the stimulation have been
reported. In one Parkinson’s disease patient who had never
suffered from depression in her life, the testing of the
stimulation caused the acute onset of tearfulness, sadness,
and despair. These symptoms remitted immediately when
the surgeon moved the stimulator away from the substan-
tia nigra, directly below the subthalamic nucleus (Bejjani
et al 1999). Parkinson’s disease researchers lead the
neuropsychiatric field in terms of understanding a dis-
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DBS to be used first in Parkinson’s disease. However, as
the neuroanatomy of other neuropsychiatric disorders
(mood, anxiety, and psychosis) becomes better under-
stood, it is conceivable that DBS may be helpful to
otherwise treatment-resistant patients, although to date
DBS has only been shown to cause depression symptoms
rather than relieve them.
The History of Vagus Nerve Stimulation (VNS)
Another, less invasive means of directly affecting central
function is to stimulate the cranial nerves that are direct
extensions of the brain. For years, scientists have been
interested in whether and how autonomic functions mod-
ulate activity in the limbic system and higher cortex.
Numerous studies have identified extensive projections of
the vagus nerve via its sensory afferent connections in the
nucleus tractus solitarius (NTS) to many brain areas
(Bailey and Bremer 1938; Dell and Olson 1951; Maclean
1990). As early as 1938, Bailey and Bremer reported that
VNS in the cat elicited synchronized activity in the orbital
cortex. In 1949, MacLean and Pribram stimulated the
vagus nerve and recorded electroencephalograms from the
cortical surface of anesthetized monkeys and found incon-
sistent slow waves generated from the lateral frontal
cortex (Maclean 1990, p. 468). Moreover, Dell and Olson
(1951) found that VNS evoked a slow-wave response in
the anterior rhinal sulcus, as well as in the amygdala, in
awake cats with high cervical spinal section.
Reasoning from this body of literature, Zabara demon-
strated the anticonvulsant action of VNS on experimental
seizures in dogs (Zabara 1985a, 1985b). Although the
vagus is an autonomic nerve, Zabara, basing his conclu-
sions on known anatomy, hypothesized that VNS could
prevent or control the motor, autonomic, and conscious
components of epilepsy. Interestingly, he also observed
that the inhibitory effect on seizures outlasted the VNS
period by approximately a factor of four in the acute
model, and probably would be much longer in a chronic
model. Zabara (1992) initially hypothesized that VNS had
two distinct antiepileptic mechanisms of action: 1) a direct
inhibition terminating the beginning or ongoing seizure
and 2) a long-lasting inhibition that increased with con-
tinued periods of stimulation to prevent seizures. Dr.
Kiffin Penry (Penry and Dean 1990) and others (Rutecki
1990) ushered in the modern use of VNS with the first
human implant for the treatment of epilepsy in 1988.
Vagus Nerve Anatomy
Traditionally the vagus nerve has been considered a
parasympathetic efferent nerve (controlling and regulating
autonomic functions such as heart rate and gastric tone);
however, the vagus (cranial nerve X) is actually a mixed
nerve composed of about 80% afferent sensory fibers
carrying information to the brain from the head, neck,
thorax, and abdomen (Foley and DuBois 1937). The
sensory afferent cell bodies of the vagus reside in the
nodose ganglion and relay information to the NTS. These
fibers are different from those that go to the other motor
nuclei of the vagus (Figure 1).
The NTS relays this incoming sensory information to
the rest of the brain through three main pathways: 1) an
autonomic feedback loop, 2) direct projections to the
Table 1. Current and Potential Somatic Interventions for the Treatment of Depression
Somatic intervention Regionally specific? Clinically applicable? Invasive?
Electroconvulsive therapy 11 (111 if induced
by magnets
1111 11 (anesthesia,
generalized seizure)
Transcranial electrical
stimulation
11 1 1 (scalp irritation)
Transcranial magnetic
stimulation
1111 111 (clinical trials
underway)
1 (painful at high
intensities)
Vagal nerve stimulation 11 (discrete brainstem
nuclei initially,
unclear if different
parameters
selectively involve
other brain regions)
111 (on the market for
epilepsy, clinical trials
in depression [see
Rush et al 2000])
111 (surgery for
generator implant)
Deep brain stimulation 1111 111 (approved in the
United States for
treatment in movement
disorders, pain
syndromes; no work in
depression yet)
1111 (brain surgery)
1, a little; 1111, a lot.
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projections to the forebrain largely through the parabra-
chial nucleus (PB) and the locus ceruleus (LC). The PB
sits adjacent to the LC (one of the primary norepinephrine-
containing areas of the brain; Figure 2). In fact, lesioning
the LC in rats eliminates the ability of VNS to suppress
seizures (Krahl et al 1998), demonstrating how important
this connection is for the antiepileptic action of VNS
(Figure 2).
The PB/LC sends direct connections to every level of
the forebrain, including the hypothalamus, and several
thalamic regions that control the insula and orbitofrontal
and prefrontal cortices. Perhaps important for mood reg-
ulation, the PB/LC has direct connections to the amygdala
and the bed nucleus of the stria terminalis—structures that
are implicated in emotion recognition and mood regulation
(Van Bockstaele et al 1999; for review of the functional
neuroanatomy of depression, see George et al 1997; Ketter
et al 1997).
These brainstem and limbic anatomic connections
have functional consequences. The oncogen C-fos is a
general marker for cellular activity. C-fos studies in rats
during VNS reveal increased activity in the amygdala,
cingulate, LC, and hypothalamus (Naritoku et al 1995).
Recently, Walker and colleagues (1999) outlined a
possible role of the NTS in how VNS reduces seizures.
By microinjecting the NTS with either g-aminobutyric
acid (GABA) agonists or glutamate antagonists, they
found that increased GABA or decreased glutamate in
the NTS blocked seizures. These findings suggest that
VNS may change NTS GABA and glutamate concen-
trations, with secondary changes in the function of
specific limbic structures noted above.
Some have suggested that because of the rotation of the
body during embryonic development the left and right
vagus nerves carry different information. This theory
implies that the right vagus is closely associated with the
cardiac atria and the left vagus with cardiac ventricular
function, perhaps explaining the lack of cardiac effects of
left VNS. Additionally, the NeuroCybernetic Prosthesis
(NCP) System stimulating electrode is intended to be
positioned below the cardiac branch of the vagus nerve.
However, this line of thinking is not totally supported by
early animal VNS research. There is even one patient who
has been treated on the right side without complication
(G.L. Morris, personal communication, October 1999). An
alternative theory holds that the cardiac functional re-
sponse is more a function of stimulation parameters than
whether the right or left nerve is stimulated.
In sum, incoming sensory (afferent) connections of the
vagus nerve provide direct projections to many of the
brain regions implicated in neuropsychiatric disorders.
These connections reveal how vagus nerve stimulation
might be a portal to the brainstem and connected regions.
These circuits likely account for the neuropsychiatric
effects of VNS, and they invite additional theoretical
considerations for potential research and clinical
applications.
Figure 1. This cross-sectional view of the brainstem illustrates
the origins of several components of the vagus nerve, a mixed
sensory and motor nerve. Efferent motor fibers originate in the
dorsal nucleus of the vagus, whereas afferent motor fibers go to
the nucleus ambiguous. Afferent sensory fibers, which make up
80% of the left vagus, terminate in the nucleus of the solitary
tract, which then projects to the midline raphe and locus and
likely is the path by which vagus nerve stimulation has antisei-
zure and other neuropsychiatric effects.
Figure 2. This diagram shows the known connections of the
nucleus tractus solitarius to the parabrachial nucleus and the
locus ceruleus (LC). Lesioning the LC in rats eliminates the
antiepileptic properties of vagus nerve stimulation. The LC is the
site of many norepinephrine-containing neurons that have im-
portant connections to the amygdala, hypothalamus, insula,
thalamus, orbitofrontal cortex, and other limbic regions linked to
mood and anxiety regulation.
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The term vagus nerve stimulation generally refers to
several different techniques used to stimulate the vagus
nerve, including those in studies in animals where the
vagus was accessed through the abdomen and diaphragm.
For practically all studies in humans, Vagus Nerve Stim-
ulation refers to stimulation of the left cervical vagus
nerve using a commercial device, the NCP System (Cy-
beronics, Houston; Schachter and Saper 1998; Figure 3).
Vagus Nerve Stimulation has been commercially available
for the treatment of resistant partial-onset seizures in epilepsy
in Europe (since 1994) and in the United States (since 1997).
About 6000 people worldwide with over 7000 patient years
of experience have had these generators implanted (W.
Duffell, Cyberonics, personal communication). Typically,
epilepsy patients considering VNS have had unsatisfactory
seizure control, commonly with several medications, and for
some VNS is an option before brain surgery.
In many ways, VNS delivered through the NCP System is
much like the very common practice of implanting cardiac
pacemakers. In both cases, a subcutaneous generator sends an
electrical signal to an organ through an implanted electrode.
In fact, the surgery for implanting the NCP generator in the
chest is much like inserting a cardiac pacemaker (Amar et al
1998). The two techniques differ, of course, in the site of
stimulation. Vagus Nerve Stimulation with the NCP System
is delivered through an implantable, multiprogrammable,
bipolar pulse generator (the size of a pocket watch) that is
implanted in the left chest wall to deliver electrical signals to
the left vagus nerve through a bipolar lead. With VNS, the
electrode is wrapped around the vagus nerve in the neck, near
the carotid artery using a separate incision, and connected to
the generator subcutaneously. Although VNS implantation
surgery was initially done almost exclusively by neurosur-
geons in patients admitted overnight to a hospital and given
general anesthesia, more recently some epilepsy patients
have had the device implanted by vascular surgeons or ear,
nose, and throat specialists via outpatient surgery with local
anesthesia.
The NCP programming wand and software, along with
a personal computer, provide telemetric communication
with the pulse generator, which enables noninvasive pro-
gramming, functional assessments (device diagnostics and
interrogation), and data retrieval. The NCP System in-
cludes mechanical and electrical safety features that min-
imize the possibility of high-frequency stimulation that
could lead to tissue damage. In addition, each patient is
given a magnet that, when held over the pulse generator,
turns off stimulation. When the magnet is removed,
normal programmed stimulation resumes.
How Effective and Safe Is VNS in Patients
with Epilepsy?
Two double-blind studies (labeled E03 [Ben-Menachem et al
1994] and E05 [Handforth et al 1998]) were conducted in
patients with epilepsy, with a total of 313 treatment-resistant
completers. In this difficult-to-treat group, the mean decline
of overall seizure frequency was about 25–30% compared
with baseline. Data from uncontrolled observations suggest
that, contrary to a tolerance effect, improvement in seizure
control is maintained or may improve over time (Morris et al
1999; Salinsky et al 1996). In the second controlled study
(E05) of VNS in patients with epilepsy, no serious adverse
events (AEs) that were judged by investigators to be probably
or definitely related to VNS occurred during treatment
(Handforth et al 1998; Schachter and Saper 1998). In three
out of 199 patients (1.5%), infection following surgery led to
device removal. Other surgery-related AEs, all of which
dissipated over time, included left vocal cord paralysis (2/199
[1%]), lower facial muscle paresis (2/199 [1%]), and pain and
accumulation of fluid over the pulse generator requiring
aspiration (1/199 [0.5%]). The perioperative AEs reported by
at least 10% of patients were pain (29%), coughing (14%),
voice alteration (13%), chest pain (12%), and nausea (10%).
The AEs reported in patients in the treatment group at
some time during treatment that were significantly in-
creased from baseline were voice alteration/hoarseness,
cough, throat pain, nonspecific pain, dyspnea, paresthesia,
Figure 3. An artist’s rendition of how the vagus is stimulated
using the NeuroCybernetic Prosthesis System. A generator about
the size of a pocket watch is implanted into the left chest wall.
Bipolar electrodes are wrapped around the left vagus higher in
the neck through a separate incision and tunneled under the skin
to the generator. A physician can control the intensity and rate of
generator firing by holding over the chest wall (and generator) a
telemetric wand connected to a portable computer (not shown).
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occurred significantly more often in the treatment group
than in the control group were dyspnea and voice alter-
ation. Adverse events were judged to be mild or moderate
99% of the time. No cognitive, sedative, visual, affective,
or coordination side effects were reported. No significant
changes occurred in Holter monitoring, in the results of
pulmonary function tests, or in subjects’ hematology
values or common chemistry values (Schachter and Saper
1998). No subjects died during the E03 or E05 controlled
studies (N 5 313). In sum, short-term AEs that are surgery
related are rare and usually resolve. Stimulation-related
AEs (i.e., those that occur only when the vagus nerve is
stimulated) can be reduced by lowering the current level.
Stimulation-related AEs can also be aborted by the patient
placing a handheld magnet over the generator that turns
the device off until a physician decreases the stimulation
intensity. These AEs rarely lead to VNS therapy discon-
tinuation (Morris et al 1999; Schachter and Saper 1998).
Although the neurology community was initially skeptical
about VNS, a recent reassessment by the American Acad-
emy of Neurology concluded that VNS for epilepsy is both
“effective and safe” (Fisher and Handforth 1999).
Does VNS Affect Cardiac Function?
It is logical to carefully evaluate potential cardiac and
gastrointestinal effects of vagus nerve stimulation. Cardiac
evaluations have been performed on more than 250 epi-
lepsy patients in clinical trials while receiving VNS.
Holter monitoring results from clinical studies in epilepsy
indicated no significant changes from baseline in cardiac
function during stimulation (Handforth et al 1998).
Only during the implantation procedure itself, six cases
of 10–20-sec asystole have been reported in epilepsy
patients. No cases were reported in either the epilepsy or
the depression clinical trials (Rush et al 2000). All six
asystoles were encountered during the diagnostics test
(Lead Test) stimulation—the first stimulation that a pa-
tient receives after implantation while in the operating
room. The Lead Test entails approximately 15 sec of
stimulation at 1.0 mA, 500 msec, and 20 Hz of VNS. Of
these six patients, three went on to have the implant (in
three others the generator and leads were removed). No
long-term sequelae have been reported from any asystolic
events in these patients. Most importantly, no cardiac
events when the device is turned on for the first time
outside the operating theater have been reported in the
clinic (Asconape et al 1999; Tatum et al 1999).
What about Longer Term Efficacy and
Tolerability?
In patients with epilepsy, the long-term efficacy of VNS is
either maintained or improved (Morris et al 1999), and the
frequency of AEs generally decreases as patients accom-
modate to the stimulation (Salinsky et al 1996). The
patient with the longest exposure to VNS has had the
system operating for 10 years (W. Duffell, Cyberonics,
personal communication, October 1999).
Extensive experience in epilepsy patients provides im-
portant safety data on VNS used continuously for 1 year or
longer. Side effects tend to decrease over time as patients
accommodate to the effects of stimulation. Two years after
initial implantation over 80% of epilepsy study patients
(142/172) continued with VNS, suggesting that it is well
tolerated over the long term (Cyberonics 1998).
How Much Does VNS Cost, Relative to Other
Treatment Modalities?
In the United States, VNS delivered with the NCP System
costs roughly $9200 for the generator and electrode. The
surgical and hospital costs for the implantation surgery
vary widely and are more difficult to quantify but are less
expensive now with the recent trend toward outpatient
surgery and local anesthesia. Typically the total charge for
the NCP System plus implantation varies from $12,000 to
$25,000 (B. Barrett, Cyberonics, personal communication,
October 1999). Most federal and private insurance com-
panies reimburse this procedure for treatment of refractory
epilepsy. After implantation the cost of the device is
minimal, as the battery lasts many years and there is no
required maintenance. Adjustments of the VNS settings
are done by treating neurologists in their office using the
personal computer and attached programming wand.
If the initial open results in depression were confirmed
in a double-blind study and FDA approval granted for
VNS treatment of depression, the cost of VNS would
compare to about $1000 for a year of a single antidepres-
sant medication or $10,000 to $30,000 for an acute course
of ECT followed by a year of maintenance ECT (Hu and
Rush 1995; Olfson et al 1998); however, since VNS is
continuous and a maintenance treatment modality, true
cost comparisons should be made against maintenance
therapies, and the relative cost of VNS improves with each
year of continued use and compares favorably to mainte-
nance ECT, as most of the costs are associated with the
initial device purchase and implantation.
Unfortunately, only a few epilepsy patients achieve full
seizure remission and are able to reduce other antiepileptic
medications. Most combine VNS with medications. Thus
VNS, as now delivered, has not been shown to be a
substitute for anticonvulsant medications. As the neuro-
scientific basis of VNS is better understood, there is hope
that refinements of VNS settings might improve the
clinical effects, with better cost savings on reductions of
concomitant medications.
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Disorders
In addition to the neuroanatomic considerations, several
additional lines of evidence provided the background for
studying whether VNS might have antidepressant effects
in treatment-resistant depression, culminating in the first
implant for this indication in July 1998 at the Medical
University of South Carolina in Charleston (Rush et al
2000), a decade after the first human epilepsy implant
(Penry and Dean 1990). These hints were 1) mood effects
of VNS observed in patients with epilepsy, 2) evidence by
positron emission tomography (PET) scans that VNS
affects the metabolism (and therefore the function) of
important limbic structures, 3) the role of anticonvulsant
medications in mood disorders, and 4) neurochemical
studies in both animals and humans revealing that VNS
alters concentrations of monoamines within the central
nervous system (CNS).
Mood Effects in Epilepsy Patients
Initial uncontrolled clinical observations and, more re-
cently, a prospective study (Harden et al 1999) and a
retrospective data analysis (Elger et al, unpublished data,
1998) suggest that VNS reduces depressive symptoms in
patients with epilepsy—reductions that are not entirely
accounted for by reduced seizure activity. During the
clinical trials of VNS for epilepsy (Ben-Menachem et al
1994; Handforth et al 1998) several investigators noted
mood improvements in their patients. Although decreased
seizure frequency likely accounted for some of these
improvements, the clinical impression was that they went
beyond those attributable to improved seizure control
alone. For example, some patients with minimal or no
improvement in seizure frequency also reported substan-
tial improvements in mood. Improved quality of life was
also seen, and without seizure frequency changes in some
patients. Thus, while no specific measures of depressive
symptoms were obtained during the epilepsy trials, these
repeated reports from independent investigators suggested
that VNS might be associated with significant mood
improvement. This is reminiscent of the “psychotropic”
effects reported in epilepsy patients treated with carbam-
azepine, which led to the clinical trials in mood-disordered
patients (Ballenger and Post 1980). In a recent prospective
study of patients with epilepsy (N 5 34), a trend toward
mood improvements was seen in the 14 who received
VNS, based on the Cornell Dysthymia Rating Scale (p ,
.1; Harden et al 1999). The significant improvement in
seizure frequency found in the VNS group was not related
to mood changes on an individual basis. The authors
suggested that VNS might improve mood independent of
seizure frequency reduction.
PET Studies of Limbic Activation
In 10 patients with epilepsy who received VNS, PET
measurements were taken three times before and then
during VNS (Henry et al 1998). The results demonstrated
increased brain blood flow from rest to during VNS in the
rostral medulla, thalamus, hypothalamus, insula, and post-
central gyrus, with greater activation on the right side
(contralateral to the device). In contrast, blood flow was
significantly decreased during stimulation bilaterally in
the hippocampus, amygdala, and cingulate gyrus. The
cingulate gyrus has been repeatedly implicated in imaging
studies of depression pathogenesis, and a decline in
cingulate activity with antidepressant response has been
seen in numerous studies (sleep deprivation [Ebert et al
1994; Wu et al 1992], selective serotonin reuptake inhib-
itor treatment [Mayberg et al 1997], symptom provocation
with drugs [Bremner et al 1997]). Thus, VNS changes in
activity of the brainstem, limbic system, and other CNS
areas are compatible with antidepressant activity.
Anticonvulsants as Mood Stabilizers
A third reason for considering the role of VNS in the
treatment of mood disorders is the substantial evidence
that anticonvulsant medications have mood-stabilizing
effects (Goodwin and Jamison 1990; Post et al 1992).
Within the last 20 years, several anticonvulsants have
found a role in mood stabilization (carbamazepine [Bal-
lenger and Post 1980; Okuma et al 1973], valproic acid
[Calabrese and Delucchi 1989; Swann et al 1997]) or as
antidepressants in (depressed phase) bipolar disorder (lam-
otrogine; Fatemi et al 1997). Further, it is well established
that our most effective antidepressant treatment, ECT, has
powerful anticonvulsant effects (Sackeim 1999; Sackeim
et al 1983). Thus, it is reasonable to hypothesize that an
effective antiepileptic device might also have antidepres-
sant or mood-stabilizing effects.
Neurochemical Changes
The basic mechanisms of action of VNS are unknown.
However, both clinical and animal studies indicate that
VNS likely results in changes in serotonin (Ben-Men-
achem et al 1995), norepinephrine (Krahl et al 1998),
GABA, and glutamate (Walker et al 1999)—neurotrans-
mitters implicated in the pathogenesis of major depression.
Vagus nerve stimulation in animals activates the LC, the
main source of CNS norepinephrine-containing neuronal
cell bodies (Naritoku et al 1995). In patients with epilepsy,
VNS appears to increase cerebrospinal fluid 5-hydroxyin-
doleacetic acid—a metabolite of serotonin (Ben-Men-
achem et al 1995). Since many of the currently available
therapies are believed to work using the same neurotrans-
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that VNS might also have antidepressant activity.
Further, there is a long history of autonomic nervous
system dysfunction in depressed patients, which is medi-
ated by the vagus nerve. These abnormalities include
differences in heart rate variability (for review, see Glass-
man 1998). Thus, if depressed patients have abnormalities
in brain regions that control the vagus nerve (top-down
regulation), then stimulating the vagus nerve might theo-
retically engage this dysfunctional circuit (a bottom-up
approach).
Summary
Several lines of evidence pointed toward the possible
benefit of VNS as an antidepressant or mood-stabilizing
treatment. These included clinical observations in epilepsy
patients, anatomic afferent connections of the left vagus
nerve to the CNS and to structures relevant to mood
regulation, the anticonvulsant activity of VNS taken in the
context of the role of anticonvulsant medications or ECT
in treating mood disorders, neurochemical studies indicat-
ing VNS effects on key neurotransmitters involved in
mood regulation, and evidence that VNS changes the
metabolic activity of key limbic system structures. This
evidence led to the initial open trial described in the
companion article in this journal (Rush et al 2000).
Other Areas of Potential Research or
Clinical Promise with VNS
Work to date has established that VNS is an effective
anticonvulsant. Recent work suggests that VNS may have
antidepressant properties. The vagus nerve is an important
route of information into the CNS. Several theories of the
anxiety disorders posit either a faulty interpretation of
peripheral information into the CNS or erratic availability
of same (Gray 1982; James 1884; Watkins et al 1998). It
is conceivable that altering the flow of this information
with VNS could have therapeutic potential in anxiety
disorders (e.g., generalized anxiety disorder, panic disor-
der) or irritable bowel syndrome.
Similarly, the vagus contains information about hunger,
satiety, and pain. Potential studies in the areas of treat-
ment-resistant obesity, addictions, and pain syndromes are
also theoretically justified. Moreover, the NTS sends
fibers into the dorsal raphe and areas that are known to
control levels of alertness. Thus, VNS might be considered
as a potential treatment for some disorders of sleep or
alertness like coma or narcolepsy. For example, a recent
study in 10 epilepsy patients found that high-intensity,
high-frequency VNS reduced total time in rapid eye
movement sleep, and such sleep was less fragmented
(Vaugh and D’Cruz 1999). Therefore, in addition to
advancing our understanding of the pathophysiology of
various neuropsychiatric disorders, VNS may have other
therapeutic applications, which are guided by the known
anatomy of vagus connections.
A recent study by Clark and colleagues hints at the
potential for VNS to be used to investigate brain circuits
involved in memory and learning (Clark et al 1999). These
researchers examined word-recognition memory in 10
patients enrolled in a clinical study of VNS for epilepsy.
Vagus stimulation administered after learning and during
memory consolidation caused intensity-dependent en-
hancement of word recognition relative to sham stimula-
tion. Other work has shown that vagotomy attenuates the
memory-enhancing properties of amphetamine.
Further Refinements in the Use of VNS
At present, the delivery of VNS involves a surgical
procedure that includes exposure and manipulation of the
carotid artery, as well as the cosmetic and other inconve-
niences of having a generator in the chest wall. As a
consequence, the NCP System is typically used in those
patients who have not responded to other therapies. In both
epilepsy and depression, some patients will receive little to
no benefit, despite having had surgery. The development
of less invasive ways of delivering VNS or predicting
which patients will benefit would likely expand the clin-
ical potential of VNS. Preliminary attempts at externally
stimulating the vagus nerve via a transcranial magnetic
stimulator have not been successful, in part due to the
difficulty of finding a reliable indication of whether TMS
has activated the vagus (H. Sackeim et al, unpublished
data, April 1998). Another possibility might be to develop
a temporary percutaneous method of stimulation.
Yet a different approach would be to identify the subset
of patients who are most likely to benefit from VNS, by
using functional neuroimaging or other measures. In this
context, a recent PET study in adults with epilepsy found
that increased blood flow in the right and left thalamus
during the initial VNS stimulation correlated with de-
creased seizures over the next few weeks (Henry et al
1999). This finding suggests that one could use functional
imaging, combined with VNS, to select patients most
likely to benefit from this therapy.
Finally, VNS can be delivered at different amplitudes
and frequencies and with different pulse widths, all at
various duty cycles (ratio of “on” time to “off” time).
More basic work would advance this area through an
understanding of how varying combinations of these
parameters affect different brain regions or influence
different neuropsychiatric conditions. It seems logical to
suggest that VNS delivered with parameters different from
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CNS effects that would in turn broaden the clinical
indications.
Conclusion
Vagus nerve stimulation, one of the newest methods to
physically alter brain function, builds on a long history of
investigation of the relationship of autonomic signals with
limbic and cortical function. Vagus nerve stimulation is
already established as a clinically useful anticonvulsant in
patients with resistant epilepsy and may have promise as
an antidepressant treatment. The known anatomic projec-
tions of the vagus nerve suggest that VNS might also have
other neuropsychiatric applications. Further research is
needed to clarify the mechanisms of action of VNS and the
potential clinical utility of this intriguing new somatic
portal into the CNS.
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sation for writing this article. NCP and VNS are trademarks of
Cyberonics.
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tract. The authors thank Burke Barrett and Dr. William Duffell of
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